Health Catalyst (NASDAQ:HCAT – Get Rating) had its target price trimmed by BTIG Research from $25.00 to $21.00 in a report published on Monday morning, The Fly reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also weighed in on HCAT. Piper Sandler lowered shares of Health Catalyst from an overweight rating to a neutral rating and dropped their price objective for the company from $21.00 to $11.00 in a research report on Tuesday, September 13th. KeyCorp assumed coverage on shares of Health Catalyst in a research report on Thursday, September 15th. They issued a sector weight rating on the stock. The Goldman Sachs Group dropped their price objective on shares of Health Catalyst from $29.00 to $18.00 and set a buy rating on the stock in a research report on Wednesday, August 10th. Stifel Nicolaus lowered shares of Health Catalyst from a buy rating to a hold rating and dropped their price objective for the company from $27.00 to $16.00 in a research report on Friday, August 5th. Finally, JPMorgan Chase & Co. lowered shares of Health Catalyst from an overweight rating to a neutral rating and dropped their price objective for the company from $20.00 to $16.00 in a research report on Friday, August 5th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Health Catalyst presently has a consensus rating of Moderate Buy and an average price target of $25.62.

Health Catalyst Trading Up 3.3 %

NASDAQ HCAT opened at $9.65 on Monday. The firm's fifty day moving average price is $12.83 and its two-hundred day moving average price is $16.29. Health Catalyst has a 1 year low of $9.03 and a 1 year high of $54.27. The firm has a market capitalization of $528.08 million, a P/E ratio of -3.30 and a beta of 1.23.

Insiders Place Their Bets

In other news, Director Duncan Gallagher acquired 8,400 shares of Health Catalyst stock in a transaction on Thursday, August 18th. The shares were purchased at an average cost of $11.69 per share, for a total transaction of $98,196.00. Following the completion of the purchase, the director now directly owns 28,805 shares of the company's stock, valued at approximately $336,730.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 1,964 shares of company stock worth $26,306 over the last ninety days. Corporate insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Health Catalyst

A number of large investors have recently bought and sold shares of HCAT. Fairfield Bush & CO. bought a new position in shares of Health Catalyst in the first quarter worth about $25,000. Macquarie Group Ltd. bought a new position in shares of Health Catalyst in the second quarter worth about $26,000. Manchester Capital Management LLC lifted its holdings in shares of Health Catalyst by 667.5% in the first quarter. Manchester Capital Management LLC now owns 1,159 shares of the company's stock worth $30,000 after acquiring an additional 1,008 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Health Catalyst in the first quarter worth about $33,000. Finally, Hardy Reed LLC bought a new position in shares of Health Catalyst in the first quarter worth about $80,000. 96.58% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Further Reading

• Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
• MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
• MO Money: Why Altria Group Stock is Rallying
• Is the Market Overreacting with Shopify Stock?
• Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Three Consumer Stocks That Could Outperform In Q4

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.